The 2019 novel coronavirus (provisionally named 2019-nCoV) is a contagious virus that causes respiratory infection. From genomic sequencing, it has been shown as a positive-sense, single-stranded RNA coronavirus. The virus was first detected in Wuhan, China, in mid-December 2019 and subsequently spreads to all provinces of China and to more than twenty other countries over the world. Creative Biostructure has established an advanced COVID-19 targeted discovery platform to offer a wide variety of products and services to accelerate your research for structure/function study and novel drug discovery.
Our featured services and products include:
Figure 1. Creative Biostructure platform of COVID-19 targets discovery and application.
What is COVID-19?
COVID-19 main proteinase (Mpro)
Treatment strategies against COVID-19
Figure 2. COVID-19 targets discovery and application.
The chief objective of global health efforts against COVID-19 remains to effectively quarantine patients and screen individuals who may be infected to limit spread. Creative Biostructure has dedicated to providing an advanced, complete and professional research services package targeting COVID-19 and established this platform to improve human health for novel vaccine/antibodies discovery. Please feel free to contact us for a detailed quote.
Based on the currently available research results on COVID-19 and our available resources and expertise, we established an advanced coronavirus service platform in structural biology, providing a wide range of contract research services in structure-based basic research, antiviral drug discovery, and vaccine development. Learn more about our integrated service platform based on structure for coronavirus research.